Date
Welcome to the London Type 1
Diabetes
Network Event
Tuesday 21st November 2017
WiFi: Connect to the cloud
No password required
2
Welcome & Introductions Dr Stephen Thomas Clinical Director
Date
Type 1 Consultation Tool
Dr Pratik Choudhary
Senior Lecturer, Consultant in Diabetes,
King’s College London November 2017
Date
Type 1 Diabetes
Commissioning Pack
National Diabetes Audit
Participation
Gemma Snell
London Diabetes Lead
November 2017
5
Type 1 Diabetes Commissioning Pack
Three main parts: 1. Service specification
2. Clinical management:
optimal pathway
3. Implementation guide
6
What is the NDA?
National Diabetes Core Audit (NDA): This annual audit of primary care
and specialist diabetes services covers care processes, treatment targets,
complications and mortality.
Collection Period: 12th June – 13th July 2017
National Diabetes Inpatient Audit (NaDIA): This is a snapshot audit of
every hospital covering inpatient care of people with diabetes.
Collection period: 25th – 29th September 2017
National Diabetes Footcare Audit (NDFA): This audit collects data about
specialist foot care services for people with diabetes.
Continuous data collection, services can commence participation at any
time
National Pregnancy in Diabetes (NPID) Audit: This audit examines
antenatal services for women with pre-gestational diabetes.
Continuous data collection however submission deadline to be included
in August 2016 annual report was 10th February 2017
7
NDA in London: 2016/17
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
Ba
rne
t
Ca
md
en
En
fie
ld
Ha
rin
ge
y
Islin
gto
n
Ba
rkin
g &
Da
ge
nh
am
City a
nd
Ha
ckn
ey
Ha
ve
rin
g
Ne
wh
am
Re
db
rid
ge
Tow
er
Ha
mle
ts
Wa
lth
am
Fo
rest
Bre
nt
Ce
ntr
al Lo
nd
on
(W
est
min
ste
r)
Ea
ling
Ha
mm
ers
mith
& F
ulh
am
Ha
rro
w
Hill
ing
do
n
Ho
un
slo
w
We
st L
on
do
n (
Ke
nsi
ng
ton
&…
Be
xle
y
Bro
mle
y
Gre
en
wic
h
Lam
be
th
Lew
ish
am
So
uth
wa
rk
Cro
yd
on
Kin
gst
on
Me
rto
n
Ric
hm
on
d
Su
tto
n
Wa
nd
swo
rth
NCL NEL NWL SEL SWL
2016/2017 Participation (%)
London participation = 96% England participation = 95%
8
Why participate in the NDA 2016/17
Comparative data to support
planning and improvement
activity
CCG accountability and
assessment
High participation ensures
high quality data across all
diabetes audits
9
Why participate in the NDA
1. Monitor
2. Compare
3. Identify trends
4. Identify priorities
5. Link to long term outcomes
6. Find omissions
7. Learn from others
8. Demonstrate excellence in
care
9. Improve care
10.Save money
http://content.digital.nhs.uk/nda_collection
10
Why participate in the NDA
1. Monitor
2. Compare
3. Identify trends
4. Identify priorities
5. Link to long term outcomes
6. Provides data for other
diabetes audits
7. Learn from others
8. Demonstrate excellence in
care
9. Improve care
10.Use money wisely
11
Useful websites
https://digital.nhs.uk/catalogue/PUB30142
http://www.londonscn.nhs.uk/publications/
Date
Commissioning Type 1 services in
South East London; Bromley –
Journey Towards Better Diabetes
Care
Jennifer Luong & David Hopkins
Senior Clinical Commissioning Manager, Bromley CCG
November 2017
13
Implementing the T1 tools in your
local area Table discussions with group feedback
Each table to discuss and answer the following questions in
relation to type 1 service provision:
1. What type 1 services are commissioned in your area?
2. What would be needed by both commissioners and providers
to implement the commissioning pack?
3. What three things will you take away with you to action after
the event to move forward implementation of the
commissioning pack?
25 minute table discussion
15 minutes for all group feedback
Please nominate someone on your table to scribe and give table
feedback
Date
Type 1 Diabetes
and the Treatment & Care
Transformation Funding
Dr Stephen Thomas
Clinical Director, London Diabetes Clinical Network
November 2017
15
Tea and coffee break
Resume at 15:15
16
Type 1 Network Workstreams: Outline
• Structured Education including T&C bid implementation Chaired by Dr Pratik Choudhary
Objectives: • Where are we: To identify how many courses are run across London and compare capacity to
requirement • Identify what plans are in place as part of the Transformation bids across London • How can we facilitate / influence change and engage people across London?
• Commissioning and resources required for type 1 diabetes services Chaired by Deborah Causer and Jennifer Luong
Objectives: • Implementation of the LCN type 1 commissioning pack • Support completion of the self-assessment by commissioners to identify gaps, priorities for
action and areas of good practice and innovation. To look at integrating responses to the survey into these assessments where data and information is not readily available.
• Type-1 patients not accessing specialist care Chaired by Dr Bobby Huda
Objectives:
• All STPs to have a dashboard to identify those at high risk and those not accessing care • All representatives from the 4 STPs to discuss what they are currently doing in their own services • To identify our at risk groups and to involve all the workstreams in this
• Access to and funding for technologies Chaired by Dr Nick Oliver
Objectives: • Defining where London is at the moment with technology accessibility across the region and
defining the variations
17
Type 1 Network Workstreams:
Development Sit in your preferred workstream area.
Answer the following questions:
1. What should the workstream working groups be developing for a
pan-London approach to type 1 diabetes?
2. How will impact of any ‘products’ developed be measured?
3. What is happening locally that can feed into the workstream?
4. How will the workstream support the treatment and care bids?
If you would like to become more involved with the working groups
please complete the EOI form on the tables.
Please nominate someone on your table to scribe and give table
feedback
Timings: 20 minutes for table discussions, 20 minutes for group feedback
NHS London Procurement Partnership
Responsible Diabetes Prescribing Group
FreeStyle Libre®:
London Update and Discussion
Vicky Chaplin
Senior Pharmacist for Medicines Optimisation
21/11/2017
• NHS LPP’s Medicines Optimisation Primary Care Workstream supports CCG medicines optimisation teams.
• A key way to achieve this is by encouraging high quality of prescribing with the aim of maximising quality of care and reducing unwarranted variation.
• Our workplan has always been led by our stakeholder’s clinical priorities and to support this we now focus on a select number of clinical areas via our task & finish groups.
• The Responsible Diabetes Prescribing Group was asked to consider the prescribing of Libre® following the announcement of its inclusion in the national Drug Tariff on the 1st of November 2017. (London Chief Pharmacist and CCG Lead meeting 28th of September).
Background
19
• The request to create London-wide supporting information for prescribing was forwarded to and agreed by the senior leads of the following regional networks:
London Diabetes Clinical Leadership Group
London Type 1 Diabetes Network
Children and Young People’s South East Coast & London Diabetes Network
Healthy London Partnership
• These groups have a variety of clinician and patient representatives and represent both adult and paediatric diabetic patients.
• Involvement of these groups resulted in numbers of suggestions for actions, and the development of potential programme of work (led by the LPP) to ensure the safe and effective introduction of FreeStyle Libre® across London.
20
Engagement with London’s clinical networks
Interim statement
• On the 13th of October, NHS LPP released interim advice for Clinical Commissioning Groups in London.
• It noted that FreeStyle Libre® was due to be added to the national Drug Tariff on the 1st of November 2017, but that it was important to note that the Drug Tariff is not a list of recommended products and NHS organisations and prescribers are not obliged to supply every item listed within it.
• It recommended that “Prescribers in primary care should not prescribe Freestyle Libre® sensors on an NHS prescription until the Freestyle Libre® device has been evaluated and approved for use through local governance processes”.
• Most areas have prescribing formularies, which list locally evaluated items approved for local prescribing.
• The mechanism for evaluation of items for formularies is via local Area Prescribing Committees or equivalent.
• It was hoped that clinician led recommendations for the region would assist NHS organisations in the evaluation process and avoid variation in practice.
15 December 2017 21
• There are four NHSE Regional Medicines Optimisation Committees who review certain items for prescribing.
• Development of the LPP statement preceded the confirmation and subsequent publication of the national RMOC position statement.
• This was released on the 1st of November and provided recommendations on:
- Where to initiate
- Patient groups to consider
- Other considerations before initiating (e.g. training, adjunctive strips)
- When to review
- Data collection
- Comments on currently available data.
22
RMOC statement
Actions following the RMOC statement release
• The London Type 1 Diabetes Network met on the 3rd of November and discussed the statement.
• They discussed the implications and potential implementation of the national statement.
• The statement is advice to area prescribing committees. APCs manage the entry of new medicines and prescribable medical devices into the NHS locally, develop prescribing guidelines and develop and maintain locally agreed formularies.
• CCGs are the statutory commissioner and only they can make a decision about whether or not and how to commission FreeStyle Libre® for their patients.
• It was agreed by the type 1 diabetes network that it was still worthwhile to take a regional approach to create the necessary implementation tools to be used in the evaluation process.
• Comments on this were fed back at the London RMOC meeting on the 9th of November.
15 December 2017 23
Draft plan for implementation – suggested initial work prior to APC consideration
• Regional treatment plans and referral pathways, including review considerations and any further details for distinct cohorts of patients (e.g. pregnancy). These will provide further information on recommended trial periods and “stop” criteria.
• Recommendations for appropriate transfer of prescribing into primary care, e.g. shared care documentation and details on necessary and available primary care training needs and methods for continuing data collection.
• Data collection tools and HCP training must be in place (and suitably peer-reviewed and user-tested) before this rolls out.
• Budget impact model required to review impact – formulary committees must review the level of funding available locally for Libre® against other items competing for local funding.
• Develop mechanism for ongoing review of data and information as more is available, e.g. NIHR cost-effectiveness review, data collected by healthcare organisations.
15 December 2017 24
25
Feedback
https://www.surveymonkey.co.uk
/r/type1event